Design and interpretation of vaccine field studies

Epidemiologic Reviews

Volumn 21, Issue 1, 1999, Pages 73-88

  Halloran, M Elizabeth ^a   Longini Jr , Ira M ^a   Struchiner, Claudio J ^b  

^a EMORY UNIVERSITY   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

DISEASE TRANSMISSION; DRUG DESIGN; INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0032822635     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017990     Document Type: Review

References (81)

1. Ross R. An application of the theory of probabilities to the study of a priori pathometry, part 1. Proc R Soc Series A 1916;92:204-30.
2. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997;146:789-803.
3. Rosenbaum PR. Observational studies. New York, NY: Springer-Verlag, 1995.
4. Robins JM, Rotnitzky A, Scharfstein DO. Sensitivity analysis for selection bias and unmeasured confounding in missing data and causal inference models. In: Halloran ME, Berry DA, eds. Statistics in epidemiology, environment and clinical trials. New York, NY: Springer-Verlag (in press).
5. Struchiner CJ, Halloran ME, Robins JM, et al. The behaviour of common measures of association used to assess a vaccination programme under complex disease transmission patterns-a computer simulation study of malaria vaccines. Int J Epidemiol 1990;19:187-96.
6. Rodrigues LC, Smith PG. Case-control approach in vaccine evaluation: efficacy and adverse effects. Epidemiol Rev 1999;21:56-72.
7. Struchiner CJ, Halloran ME, Brunet RC, et al. Malaria vaccines: lessons from field trials. Cadernos do Saúde Pública 1994;10(Suppl 2):310-26.
8. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984;13: 87-93.
9. Greenwood M, Yule GU. The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med 1915;8(part 2):113-94.
10. Fox JP, Hall CE, Elveback LR. Epidemiology: man and disease. New York, NY: MacMillan, 1970.
11. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985;63: 1055-68.
12. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev 1988;10:212-41.
13. Fine PEM, Clarkson JA, Miller E. The efficacy of pertussis vaccines under conditions of household exposure: further analysis of the 1978-80 PHLS/ERL study in 21 area health authorities in England. Int J Epidemiol 1988;17:635-42.
14. Kendrick P, Eldering G. A study in active immunization against pertussis. Am J Hyg 1939;29B:133-53.
15. Halloran ME, Struchiner CJ. Study designs for dependent happenings. Epidemiology 1991;2:331-8.
16. Rhodes PH, Halloran ME, Longini IM Jr. Counting process models for differentiating exposure to infection and susceptibility. J R Stat Soc B 1996;58:751-62.
17. Urdaneta M, Prata A, Struchiner CJ, et al. Evaluation of SPf66 malaria vaccine efficacy in Brazil. Am J Trop Med Hyg 1998;58:378-85.
18. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-12.
19. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990;335:270-3.
20. Durham LK, Halloran ME, Longini IM Jr, et al. Smoothing methods for exploring time-dependent vaccine effects. Appl Stat 1999:48:395-407.
21. Hastie T, Tibshirani R. Varying-coefficients models. J R Stal Soc B, 1993;55:757-96.
22. Whitehead J. Fitting Cox's regression model to survival data using GLIM. Appl Stat 1980;29:268-75.
23. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982:69:239-41.
24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81:515-26.
25. Durham LK, Longini IM Jr, Halloran ME, et al. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 1998;147:948-59.
26. Halloran ME, Haber M, Longini IM Jr, et al. Direct and indirect effects in vaccine field efficacy and effectiveness. Am J Epidemiol 1991;133:323-31.
27. Haber M, Longini IM Jr, Halloran ME. Measures of the effects of vaccination in a randomly mixing population. Int J Epidemiol 1991;20:300-10.
28. Halloran ME, Haber M, Longini IM Jr. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 1992;136:328-43.
29. Brunet RC, Struchiner CJ, Halloran ME. On the distribution of vaccine proteclion under heterogeneous response. Math Biosci 1993;116:111-25.
30. Longini IM Jr, Halloran ME. A frailty mixture model for estimating vaccine efficacy. Appl Stal 1996;45:165-73.
31. Halloran ME, Longini IM Jr, Struchiner CJ. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol 1996;144:83-97.
32. Halloran ME, Struchiner CJ, Spielman A. Modeling malaria vaccines. II: Population effects of stage-specific malaria vaccines dependent on natural boosting. Math Biosc 1989;94: 115-49.
33. Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography 1979;16:439-54.
34. Farewell VT. The use of mixture models for the analysis of survival data wilh long-term survivors. Biometrics 1982;38: 1041-6.
35. Haber M, Miao G. Frailty models for estimating vaccine efficacy from continuous time data. In: Bulletin of the International Statistical Institute, 51st Session, Islanbul, Turkey, August 1997:247-8.
36. Greenland S, Robins JM. Identifiability, exchangeability, and epidemiological confounding. Int J Epidemiol 1986;15:412-19.
37. Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol 1987;125:761-8.
38. Gail MH. Adjusting for covariates that have the same distribution in exposed and unexposed cohorts. In: Moolgavkar SH, Prentice RL, eds. Modern statistical methods in chronic disease epidemiology. New York, NY: Wiley, 1986:3-18.
39. Gail MH. The effect of pooling across strata in perfectly balanced studies. Biometrics 1988;44:151-62.
40. Gail MH, Tan WY, Piantadosi S. Tests for no treatment effect in randomized clinical trials. Biometrika 1988;75:57-64.
41. Gail MH, Wieand S, Piantadosi S. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. Biometrika 1984;71:431-44.
42. Struchiner CJ, Halloran ME. Randomization and baseline transmission in vaccine field trials. Technical report, biostatistics. Atlanta, GA: Emory University, 1996.
43. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987;9:866-83.
44. Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat 1978;7:34-58.
45. Holland PW. Statistics and causal inference. J Am Stat Assoc 1986;81:945-60.
46. Halloran ME, Struchiner CJ. Causal inference for infectious diseases. Epidemiology 1995;6:142-51.
47. Gilbert PB, Self SG, Ashby MA. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics 1998;54:799-814.
48. Koopman JS, Little RJ. Assessing HIV vaccine effects. Am J Epidemiol 1995;142:1113-20.
49. Longini IM Jr, Datta S, Halloran ME. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:440-7.
50. Halloran ME. [Evaluating HIV vaccines] Discussion. Stat Med 1998;15:2405-12.
51. Longini IM Jr, Sagatelian K, Rida WN, et al. Optimal vaccine trial design when estimating vaccine efficacy for sus-ceptibility and infectiousness from multiple populations. Stat Med 1998;17:1121-36.
52. Datta S, Halloran ME, Longini IM Jr. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. Stat Med 1998;17:185-200.
53. Longini IM Jr, Koopman JS. Household and community transmission parameters from final distributions of infections in households. Biometrics 1982;38:115-26.
54. Halloran ME, Longini IM Jr, Haber MJ, et al. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Stat Med 1994;13:357-77.
55. Golm GT, Halloran ME, Longini IM Jr. Semi-parametric models for mismeasured exposure information in vaccine trials. Stat Med 1998;17:2335-52.
56. Golm GT, Halloran ME, Longini IM Jr. Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials. Biometrics 1999;55: 94-101.
57. Little RJA, Rubin DB. Statistical analysis with missing data. New York, NY: Wiley, 1987.
58. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73: 1-11.
59. Flanders WD, Greenland S. Analytic methods for two-stage case-control studies and other stratified designs. Stat Med 1991;10:739-47.
60. Pepe MS, Fleming TR. A nonparametric method for dealing with mismeasured covariate data. J Am Stat Assoc 1991; 86:108-13.
61. Reilly M, Pepe MS. A mean score method for missing and auxiliary covariate data in regression models. Biometrika 1995;82:299-314.
62. Robins JM, Rotnitzky A, Zhao LP. Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 1994;89:846-66.
63. Fine PEM. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
64. Clemens J, Brenner R, Rao M, et al. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996;275:390-7.
65. Hayes R, Mosha F, Nicoll A, et al. A community trial of the impact of improved sexually transmitted disease treatment on HIV epidemic in rural Tanzania. 1. Design. AIDS 1995;9: 919-26.
66. Monto AS, Davenport FM, Napier JA, et al. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull World Health Organ 1969;41:537-42.
67. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997;94:6571-6.
68. Lipsitch M. Bacterial vaccines and serotype replacement: lessons fron Haemophilus influenza and prospects for Streptococcuspneumoniae. Emerg Infect Dis 1999;5:336-45.
69. Koepsell TD, Wagner EH, Cheadle AC, et al. Selected methodological issues in evaluating community-based health promotion and disease prevention programs. Annu Rev Public Health 1992;13:31-57.
70. Donner A. Some aspects of the design and analysis of cluster randomization trials. Appl Stat 1998;47:95-114.
71. Prentice RL, Sheppard L. Aggregate data studies of disease risk factors. Biometrika 1995;82:113-25.
72. Klar N, Gyorkos T, Donner A. Cluster randomization trials in tropical medicine: a case study. Trans R Soc Trop Med Hyg 1995;89:454-9.
73. Murray DM. Design and analysis of group-randomized trials. New York, NY: Oxford University Press, 1998.
74. Greenland S, Robins JM. Conceptual problems in the definition and interpretation of attributable fraction. Am J Epidemiol 128:1185-97, 1988.
75. Robins JM, Greenland S. Estimability and estimation of excess and etiologic fraction. Stat Med 1989;8:845-59.
76. De Finetti B. Theory of probability: a critical introductory treatment. New York, NY: Wiley, 1974.
77. Norwood PK, Sampson AR. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat Med 1988;7:1023-30.
78. Tsong Y. False alarm rates of statistical methods used in determining increased frequency of reports on adverse drug reaction. J Biopharm Stat 1992;2:9-30.
79. Fine PEM, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 1992;136:121-35.
80. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluations. Biometrics 1995;51:228-35.
81. Halloran ME, Longini IM Jr, Struchiner CJ. Design, analysis, and interpretation of vaccine studies. New York, NY: Springer-Verlag (in press).